case_images: PMC11031120_01
case_images: A case study for better interpretability. A phase III trial for heart failure was conducted across multiple countries and involved 4,822 patients. Our method estimates the trial's chances of approval at 0.287, providing drug developers with confidence in the future prospects of the treatment. In addition, the heavier weighting in the lower components compared to the upper ones suggests that efficacy might be a key issue in the trial. This aligns with the actual outcomes observed. More details can be referred to Methods.
case_images: hds.0126.fig.006.jpg
case_images: PMC11031120_01_hds.0126.fig.006.jpg
case_images: F6
case_images: To show our method can predict clinical trial approval accurately and potentially save huge unnecessary costs in the case of failure, we demonstrate a representative example in Fig. 6. We also visualize the weight of each edge in the interaction graph to interpret the results in Fig. 6.